IRIS
MENNA, PIERANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.682
NA - Nord America 542
EU - Europa 341
SA - Sud America 13
OC - Oceania 12
AF - Africa 8
Totale 4.598
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.112
US - Stati Uniti d'America 523
HK - Hong Kong 262
CN - Cina 258
GB - Regno Unito 93
DE - Germania 73
CZ - Repubblica Ceca 54
IT - Italia 41
FI - Finlandia 25
IN - India 21
NL - Olanda 16
CA - Canada 14
AU - Australia 12
BR - Brasile 9
ZA - Sudafrica 8
BE - Belgio 6
UA - Ucraina 6
JP - Giappone 4
TR - Turchia 4
TW - Taiwan 4
AT - Austria 3
EE - Estonia 3
ID - Indonesia 3
MX - Messico 3
PL - Polonia 3
PT - Portogallo 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AR - Argentina 2
CL - Cile 2
ES - Italia 2
FR - Francia 2
GE - Georgia 2
IE - Irlanda 2
PK - Pakistan 2
SE - Svezia 2
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BY - Bielorussia 1
DM - Dominica 1
DO - Repubblica Dominicana 1
IQ - Iraq 1
KR - Corea 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LT - Lituania 1
PH - Filippine 1
RO - Romania 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
YE - Yemen 1
Totale 4.598
Salva come PNG Salva come JPEG
Città #
Hong Kong 260
Singapore 196
Ashburn 137
Boardman 106
Hefei 93
London 81
Shanghai 59
Munich 43
Brno 35
Los Angeles 29
Rome 26
San Francisco 26
Redmond 20
Council Bluffs 18
Olomouc 17
Pune 17
Amsterdam 16
Turku 14
Helsinki 11
Washington 11
Santa Clara 10
Seattle 10
Guangzhou 9
Toronto 8
Melbourne 6
New York 6
São Paulo 6
Beijing 4
Brooklyn 4
Dallas 4
Haikou 4
Manchester 4
Boston 3
Canberra 3
Chicago 3
Hanover 3
Johannesburg 3
Mol 3
Oklahoma City 3
Sydney 3
Taipei 3
Tokyo 3
Wuhan 3
Ankara 2
Aversa 2
Dublin 2
Genoa 2
Hangzhou 2
Hasselt 2
Iowa City 2
Lodz 2
Mexico City 2
New Delhi 2
North Liberty 2
Nuremberg 2
Paris 2
Porto 2
Shanwei 2
Shenzhen 2
Stockholm 2
Tallinn 2
Tbilisi 2
The Dalles 2
Tirana 2
West Jordan 2
Xiamen 2
Zhengzhou 2
Almaty 1
Ansan-si 1
Berlin 1
Brussels 1
Buenos Aires 1
Central District 1
Centurion 1
Changchun 1
Changsha 1
Charlotte 1
Chengdu 1
Chennai 1
Chongqing 1
Clifton 1
Colombo 1
Columbia 1
Concord 1
Dalian 1
Denver 1
Dhaka 1
Frankfurt am Main 1
Fuyang 1
Fuzhou 1
Grand Rapids 1
Guiyang 1
Handan 1
Hicksville 1
Hradec Králové 1
Jinan 1
Kunming 1
Linfen 1
Lisbon 1
Lomas de Zamora 1
Totale 1.404
Salva come PNG Salva come JPEG
Nome #
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 189
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 175
Cancer drugs and QT prolongation: weighing risk against benefit 175
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 174
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 168
Minimal sampling colistin pharmacokinetics in critically ill patients 166
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 164
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 162
Cardio-oncology in clinical studies and real life 161
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 160
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 152
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 149
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 144
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 130
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 103
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 98
Anthracyclines 97
Anthracycline Cardiotoxicity 93
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 93
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 87
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 87
Anthracycline Cardiotoxicity 81
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 76
An introduction to the metabolic determinants of anthracycline cardiotoxicity 69
Cardiotoxicity of antitumor drugs 65
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 63
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 61
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 54
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 37
What is cardiotoxicity? 37
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 34
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 31
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 31
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 30
Pharmacology of Cardio-Oncology 30
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 29
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 29
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 29
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 29
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 28
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 28
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 26
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 26
Isavuconazole: case report and pharmacokinetic considerations 25
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 24
Development and Validation of a UHPLC-MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples 23
MEN 10755 : A novel disaccharide anthracycline with a reduced level of formation and [4Fe-4S]-reactivity of toxic alcohol metabolite in human heart . 23
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 22
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 22
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 22
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 22
Matters of the heart: The case of TNF-alpha targeting drugs 21
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 21
MEN 10755: a novel disaccaride anthracycline with a reduced level of formation and [4Fe-4S]- reactivity of toxic alcohol metabolite in human myocardium 21
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 20
The concomitant management of cancer therapy and cardiac therapy 20
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 20
Pharmacological Foundation of Cardio-Oncology 19
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 19
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 19
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 18
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 18
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 18
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 18
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 17
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 17
Doxorubicin degradation in cardiomyocytes 16
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 16
In ®Entresto we trust 16
Translating molecular mechanisms into clinical facts 16
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 16
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 16
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 16
Molecular determinants of the reduced cardiotoxicity of epirubicin 16
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 16
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 15
Recommendations for the harmonization of reference intervals in the therapeutic monitoring of antiepileptic drugs/Indicazioni per l’armonizzazione degli intervalli di riferimento nel monitoraggio terapeutico di farmaci antiepilettici 15
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 15
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 15
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 15
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 15
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 14
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition J. Biol. Chem 14
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 14
Do you know pixantrone? 13
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 13
Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 13
Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry 13
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 12
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 12
The reality of pixantrone in real life 11
Humans and Rodents: The Case of hOAT4 and mOat5 8
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 8
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 3
Totale 4.701
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.358
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.358
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022218 0 4 0 0 0 0 1 92 4 0 5 112
2022/202356 2 1 1 4 2 2 15 0 3 3 22 1
2023/2024333 6 35 11 15 37 146 1 16 2 8 4 52
2024/20254.043 102 36 123 15 45 77 40 21 250 263 1.446 1.625
2025/202651 51 0 0 0 0 0 0 0 0 0 0 0
Totale 4.701